TLR4/MYD88-dependent, LPS-induced synthesis of PGE2 by macrophages or dendritic cells prevents anti-CD3-mediated CD95L upregulation in T cells

Cell Death and Differentiation

Volumn 15, Issue 12, 2008, Pages 1901-1909

  Weinlich, R ^a,b   Bortoluci, K R ^a   Chehab, C F ^a   Serezani, C H ^c   Ulbrich, A G ^a,b   Peters Golden, M ^c   Russo, M ^a   Amarante Mendes, G P ^a,b,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Institute for Investigation in Immunology   (Brazil)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FAS LIGAND; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROTEIN EP2; PROTEIN EP4; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL DEATH; CELL KILLING; CELL PROTECTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVATION; FEMALE; KNOCKOUT MOUSE; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANIMALS; ANTIGENS, CD3; CELL DEATH; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOPROTECTION; DENDRITIC CELLS; DINOPROSTONE; FAS LIGAND PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTORS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MYELOID DIFFERENTIATION FACTOR 88; RECEPTORS, PROSTAGLANDIN E; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

MUS;

EID: 56349145549     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2008.128     Document Type: Article

References (41)

1. Huang AY, Qi H, Germain RN. Illuminating the landscape of in vivo immunity: Insights from dynamic in situ imaging of secondary lymphoid tissues. Immunity 2004; 21: 331-339.
2. Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P. Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol 2002; 14: 354-359.
3. Amarante-Mendes GP, Green DR. The regulation of apoptotic cell death. Braz J Med Biol Res 1999; 32: 1053-1061.
4. Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24: 321-352.
5. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
6. Pasare C, Medzhitov R. Toll-like receptors: Linking innate and adaptive immunity. Adv Exp Med Biol 2005; 560: 11-18.
7. Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005; 6: 163-170.
8. Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004; 113: 153-162.
9. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433.
10. Rhee SH, Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J Biol Chem 2000; 275: 34035-34040.
11. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144-150.
12. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-448.
13. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F et al Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-444.
14. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282: 11613-11617.
15. Aronoff DM, Canetti C, Serezani CH, Luo M, Peters-Golden M. Cutting edge: Macrophage inhibition by cyclic DMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J Immunol 2005; 174: 595-599.
16. Harizi H, Gualde N. The impact of eicosanoids on the crosstalk between innate and adaptive immunity: The key roles of dendritic cells. Tissue Antigens 2005; 65: 507-514.
17. Okano M, Sugata Y, Fujiwara T, Matsumoto R, Nishibori M, Shimizu K et al. E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology 2006; 118: 343-352.
18. Brown DM, Warner GL, Ales-Martinez JE, Scott DW, Phipps RP. Prostaglandin E2 induces apoptosis in immature normal and malignant B lymphocytes. Clin Immunol Immunopathol 1992; 63: 221-229.
19. Mastino A, Piacentini M, Grelli S, Favalli C, Autuori F, Tentori L et al. Induction of apoptosis in thymocytes by prostaglandin E2 in vivo. Dev Immunol 1992; 2: 263-271.
20. Pica F, Franzese O, D'Onofrio C, Bonmassar E, Favalli C, Garaci E. Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: A c-Myc-dependent and Bcl-2-independent associated pathway. J Pharmacol Exp Ther 1996; 277: 1793-1800.
21. Mastino A, Grelli S, Piacentini M, Oliverio S, Favalli C, Perno CF et al. Correlation between induction of lymphocyte apoptosis and prostaglandin E2 production by macrophages infected with HIV. Cell Immunol 1993; 152: 120-130.
22. Jones CP, Paula Neto HA, Assreuy J, Vargaftig BB, Gaspar Elsas MI, Elsas PX. Prostaglandin E2 and dexamethasone regulate eosinophil differentiation and survival through a nitric oxide- and CD95-dependent pathway. Nitric Oxide 2004; 11: 184-193.
23. Pace E, Bruno TF, Berenger B, Mody CH, Melis M, Ferraro M et al. Elevated expression of prostaglandin receptor and increased release of prostaglandin E2 maintain the survival of CD45RO+ T cells in the inflamed human pleural space. Immunology 2007; 121: 427-436.
24. Goetzl EJ, An S, Zeng L. Specific suppression by prostaglandin E2 of activation-induced apoptosis of human CD4+CD8+ T lymphoblasts. J Immunol 1995; 154: 1041-1047.
25. Porter BO, Malek TR. Prostaglandin E2 inhibits T cell activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction. Eur J Immunol 1999; 29: 2360-2365.
26. Yarovinsky TO, Hunninghake GW. Lung fibroblasts inhibit activation-induced death of T cells through PGE(2)-dependent mechanisms. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1248-L1256.
27. Thompson BS, Mata-Haro V, Casella CR, Mitchell TC. Peptide-stimulated DO11.10T cells divide well but accumulate poorly in the absence of TLR agonist treatment. Eur J Immunol 2005; 35: 3196-3208.
28. Ivanov VN, Lee RK, Podack ER, Malek TR. Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: A potential role for transcription factor NF-kappa B. Oncogene 1997; 14: 2455-2464.
29. Perkins DJ, Kremsner PG, Weinberg JB. Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria. J Infect Dis 2001; 183: 113-118.
30. Ganapathy V, Gurlo T, Jarstadmarken HO, von Grafenstein H. Regulation of TCR-induced IFN-gamma release from islet-reactive non-obese diabetic CD8(+) T cells by prostaglandin E(2) receptor signaling. Int Immunol 2000; 12: 851-860.
31. Decallonne B, van Etten E, Giulietti A, Casteels K, Overbergh L, Bouillon R et al. Defect in activation-induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun 2003; 20 219-226.
32. Arreaza G, Salojin K, Yang W, Zhang J, Gill B, Mi QS et al. Deficient activation and resistance to activation-induced apoptosis of CD8+ T cells is associated with defective peripheral tolerance in nonobese diabetic mice. Clin Immunol 2003; 107: 103-115.
33. Chase HP, Williams RL, Dupont J. Increased prostaglandin synthesis in childhood diabetes mellitus. J Pediatr 1979; 94: 185-189.
34. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker DS, She JX et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 1999; 104: 515-523.
35. Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases. Clin Immunol 2006; 119 229-240.
36. Brumatti G, Weinlich R, Chehab CF, Yon M, Amarante-Mendes GP. Comparison of the antiapoptotic effects of Bcr-Abl, Bcl-2 and Bcl-x(L) following diverse apoptogenic stimuli. FEBS Lett 2003; 541: 57-63.
37. Bastos KR, Alvarez JM, Marinho CR, Rizzo LV, Lima MR. Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J Leukoc Biol 2002; 71: 271-278.
38. Bastos KR, de Deus Vieira de Moraes L, Zago CA, Marinho CR, Russo M, Alvarez JM et al. Analysis of the activation profile of dendritic cells derived from the bone marrow of interleukin-12/ interleukin-23-deficient mice. Immunology 2005; 114: 499-506.
39. Amarante-Mendes GP, Jascur T, Nishioka WK, Mustelin T, Green DR. Bcr-Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity. Cell Death Differ 1997; 4: 548-554.
40. McGahon AJ, Brown DG, Martin SJ, Amarante-Mendes GP, Cotter TG, Cohen GM et al. Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: Characterization of the apoptotic death. Cell Death Differ 1997; 4: 95-104.
41. Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ 2003; 10: 592-598.